Menu
Close
.svg)
Several years ago, I was commissioned by one of our pharmaceutical industry clients to conduct a somewhat unusual piece of primary market research. The company was developing a medicine for children and wanted to evaluate how young patients would react to different versions of the tablet itself. They called it “trade dress” research. Among the alternatives was something I had never encountered before: a pill with a subtle, sparkly sheen.
I confess that my initial reaction was skepticism. A sparkly medicine? It sounded more like confectionery than pharmacology. But as I got into the interviews, the children, and many of their parents, thought otherwise.
To them, the shimmer made the tablet seem less clinical, less intimidating and, remarkably, a little more fun. This was not a medicine intended for some trifling childhood ailment. The disease was serious, which made the reaction all the more striking. Something as apparently inconsequential as the appearance of a pill had altered the emotional tenor of taking it. The medicine had not become more efficacious. Its pharmacology was unchanged. But the psychological experience of taking it had shifted.
There was science behind the sparkle. In 2006, the US FDA permitted certain pearlescent pigments for use in oral medicines, allowing manufacturers to create metallic, satiny or shimmering finishes. Yet what stayed with me from that piece of research was not the chemistry of the coating. It was the reminder that the people who take medicines encounter them rather differently from the people who develop them.
A pharmaceutical scientist would quite properly object that “formulation” encompasses considerably more than what a medicine looks or feels like. It includes the active pharmaceutical ingredient (API), excipients and a host of technical decisions required to turn a molecule into a viable medicine. But from the perspective of a pharmaceutical market researcher like me, there is also a patient-facing dimension to formulation: the physical form in which that medicine eventually arrives in somebody’s hand, mouth and daily routine.
A tablet has a size, shape, color, coating and texture. It may be scored or unscored, round or oblong, slick or stubbornly chalky. A liquid has a flavour, smell, viscosity and mouthfeel. A medicine may arrive as a capsule, sachet, powder, suspension, dissolvable formulation or something else altogether. And alongside these characteristics sits the regimen itself: how much must be taken, how often, under what conditions and with how much inconvenience.
These details can appear decidedly secondary beside the molecule itself. But to the person taking the medicine, or helping a loved one to take it, they are anything but. The molecule determines what a medicine can do. The formulation helps determine what it is like to live with it.
For R&D and commercial teams, that makes formulation research particularly valuable whenever meaningful choices remain about the product patients will ultimately use. When conducted effectively, such research can distinguish between what merely looks preferable on paper and what patients, care partners and healthcare professionals (HCPs) may actually value in practice. It can also uncover points of differentiation that may influence whether a patient is willing to start a medicine, persist with it or, in a competitive market, switch to it.
No one wants to have to take a pill. But if you have to, you might as well find it acceptable.
There is now a respectable body of evidence behind what patients have been telling researchers for years. Brett Hauber and colleagues, in a 2024 scoping review of research into solid oral dosage forms, identified four broad dimensions of patient acceptability: appearance, swallowability, palatability and handling. Across the 19 studies they evaluated, size, shape and texture emerged as particularly consequential.
Size sounds straightforward. Smaller pills ought to be better. Except that they are not always.
Hauber and his colleagues learned that some patients preferred a larger number of smaller tablets, while others preferred fewer, larger ones. In one study, 42% chose more smaller tablets and 36% fewer larger tablets. Smaller tablets can be easier to swallow, but they can also be harder to handle. Very small pills may be troublesome for someone with impaired eyesight or dexterity to retrieve from a blister pack, pick up from a counter or distinguish from other medicines.
Such findings are a useful antidote to the notion that there is a perfect pill waiting to be discovered. There is not. There are instead a series of compromises and trade-offs, whose importance varies by patient type, therapeutic category, regimen and circumstance.
The consequences can extend beyond preference. In a 2024 study published in Scientific Reports, Tilaye Arega Moges and colleagues surveyed 388 adult patients taking medication. More than half reported a history of treatment discontinuation. Frequency of administration was the most commonly cited contributor, followed by dosage form, and both dosage-form preference and administration frequency were significantly associated with discontinuation.
None of this is an argument that color or tablet size somehow outmatches efficacy, safety or tolerability. It is an argument that clinical performance and product experience coexist. A medicine can be clinically excellent and unnecessarily awkward to use.
Children make this particularly vivid. Hauber’s review included research in which children were less able than adults to swallow a 7.5-mm tablet, while another study found swallowability declined as pediatric patients progressed from 6-mm to 8-mm and 10-mm tablets. Taste can be even more unforgiving. Work by Venables and colleagues found taste to be implicated in 64% of oral formulations refused by children. Bitter flavours and unpleasant aftertastes are not minor matters when the medicine has to make the journey past a suspicious six-year-old every morning.
My sparkly pill begins to look rather less frivolous.
Good formulation research begins with an unglamorous question: what decision are we actually trying to make?
Early in development, the remit may be broad. Which dosage forms are viable and acceptable? Which attributes matter most to patients? Where are the thresholds beyond which tablet size, dosing frequency, volume, taste or pill burden become show-stoppers? Later, the questions may become more nuanced. Which of two candidate formulations is preferred? What is driving that preference? Is the difference large enough to matter commercially? Could it affect a physician’s willingness to prescribe, a patient’s willingness to start, or either party’s propensity to switch?
The research method should be tailored accordingly.
Qualitative work is particularly useful when the terrain is still poorly mapped. A rating of seven out of ten tells you that somebody finds a formulation reasonably acceptable. It does not tell you why. A 1:1 depth interview can uncover the association between a large tablet and a previous choking episode, a parent’s dread of negotiating another unpleasant-tasting medicine with a child, or the fact that a sachet looks convenient until the respondent envisions preparing it in the middle of a working day.
Quantitative research becomes more useful when the problem is one of magnitude and trade-off. Katie Stewart and colleagues reviewed 42 quantitative studies across diabetes, oncology, osteoporosis and autoimmune disease and found that route of administration, dosing frequency, timing, pill burden and treatment duration could all exert measurable effects on preference. Their conclusion is particularly germane to drug developers: patient preferences concerning formulation, dosing and administration can help inform target product profiles during development.
This is where discrete-choice experiments, conjoint techniques and other preference methods can become powerful. The useful question is seldom whether patients prefer smaller tablets. Of course many do. The more revealing question is how much size matters when something else must be surrendered in exchange. Would someone accept two larger tablets rather than four smaller ones? Would better taste offset increased dosing frequency? Would the convenience of a sachet survive the nuisance of mixing it, and what it can be mixed with? Would an infrequent injection be preferable to a daily oral medicine?
The answers are unlikely to be identical for a new-to-treatment patient versus someone who has spent years injecting themselves.
Whenever practical, formulation research should make the experience as realistic and tangible as the development stage permits. A photograph is better than a verbal description. A photograph next to a familiar object, such as a coin, is better still. A dimensional model or realistic prototype adds another layer. And where appropriate protocols permit it, placebo formulations can allow researchers to investigate swallowing, coating, texture, taste and mouthfeel rather than asking respondents to imagine them.
There is good precedent for doing so. The literature reviewed by Hauber includes prospective placebo-controlled experiments, crossover designs and mixed-method studies. Researchers at University College London have used 3D-printed medicines to investigate acceptability, while Kazuhiro Kabeya and colleagues in Japan used 3D-printed model tablets and capsules to study preferences concerning shape and size.
Realism, however, must be accompanied by disciplined logistics. Samples must reach the correct respondents on time and in the correct condition. Instructions must be unambiguous. Accountability, storage and disposal may matter. Researchers must be fastidious about what participants are permitted to see, touch, taste or swallow. A beautifully conceived exercise that founders because half the samples are languishing in a mail sorting depot is not beautifully conceived research.
Nor should every formulation be interrogated with the same questionnaire. Tablets raise questions about dimensions, shape, coating, swallowability, pill burden and aftertaste. Liquids bring flavor, smell, viscosity, aftertaste, mouthfeel, dosing volume and measuring into play. Sachets introduce portability, preparation, mixing and the circumstances in which administration takes place. Devices add another layer of human-factors and usability considerations. The research battery should follow the product, the development stage and the commercial decision, rather than being treated as a fixed instrument.
Patients are indispensable to this work, but they need not be the only respondents.
Prescribing HCPs see these human elements of formulation through a different lens. They know which patients balk at injections, struggle with dysphagia, complain about pill burden or fail to follow complicated regimens. Formulation can also affect their own treatment choices. The relevant question may therefore be not simply whether an HCP likes a formulation, but whether it changes the likelihood of prescribing, initiating, recommending or switching a patient to the medicine.
Pharmacists provide yet another vantage point. They encounter the practical afterlife of formulation decisions: questions about crushing and splitting, storage, confusing changes in pill appearance, packaging, administration technique and the small acts of improvisation that occur when the prescribed product does not fit comfortably into somebody’s life. They may also be the people who have to explain how the medicine should be administered and help patients or care partners navigate the practicalities.
These perspectives should not be tossed into the same analytical stew. Patients can illuminate what it is like to live with a medicine. HCPs can tell us how its physical and administration characteristics may influence treatment decisions. Pharmacists can expose frictions that become visible only once the medicine is in the patient's hands. Depending on the development question, all three may be useful.
The timing matters too. Hauber and colleagues note that patient acceptability and preferences have historically been investigated more often around or after launch than during early development. That seems rather late to discover that patients dislike the thing they may have to swallow every day for years.
Pharmaceutical companies quite properly spend heavily on researching strategy, communication, promotional approaches and sales materials. Yet years before the first advertisement appears or the first sales representative calls on a physician, teams may be making decisions about an experience patients will repeat hundreds or thousands of times.
Chemistry, pharmacokinetics, manufacturing, stability, regulation and cost will inevitably constrain what is possible. Patient preference cannot offset or repeal the laws of pharmaceutical science. But where development teams retain genuine latitude, there is little virtue in guessing.
The best formulation is not invariably the smallest pill, the prettiest tablet, the sweetest liquid or the least frequent dose. It is the one that preserves what the medicine needs to do for the right patient type while making the business of taking it as acceptable as circumstances allow.
And every so often, as a group of children taught me years ago, the answer may even involve a little sparkle.
